Table 4.
Adverse Events after the Start of Irinotecan Attributed as Definitely, Probably, or Possibly Related to Treatment (n=95)
| Grade | |||||
|---|---|---|---|---|---|
| Category | 1 | 2 | 3 | 4 | 5 |
| Allergy/immunology | 3 | 1 | 0 | 0 | 0 |
| Auditory/ear | 1 | 3 | 1 | 0 | 0 |
| Blood/bone marrow | 20 | 20 | 26 | 10 | 0 |
| Cardiac arrhythmia | 1 | 0 | 0 | 0 | 0 |
| Cardiac general | 0 | 1 | 0 | 0 | 0 |
| Coagulation | 1 | 0 | 0 | 0 | 0 |
| Constitutional symptoms | 31 | 27 | 15 | 1 | 0 |
| Dermatology/skin | 21 | 16 | 1 | 0 | 0 |
| Endocrine | 3 | 0 | 0 | 0 | 0 |
| Gastrointestinal | 37 | 31 | 10 | 0 | 0 |
| Hemorrhage/bleeding | 1 | 0 | 1 | 0 | 0 |
| Hepatobiliary/pancreas | 1 | 0 | 0 | 0 | 0 |
| Infection | 3 | 4 | 7 | 2 | 0 |
| Lymphatics | 5 | 1 | 0 | 0 | 0 |
| Metabolic/laboratory | 35 | 9 | 7 | 0 | 0 |
| Musculoskeletal/soft tissue | 4 | 5 | 2 | 0 | 0 |
| Neurology | 13 | 16 | 8 | 0 | 0 |
| Ocular/visual | 8 | 3 | 0 | 0 | 0 |
| Pain | 19 | 9 | 2 | 0 | 0 |
| Pulmonary/upper respiratory | 7 | 3 | 3 | 1 | 0 |
| Renal/genitourinary | 3 | 0 | 0 | 0 | 0 |
| Sexual/reproductive function | 0 | 1 | 0 | 0 | 0 |
| Vascular | 1 | 1 | 1 | 1 | 0 |
| Worst non-hematologic | 15 (16%) |
39 (41%) |
31 (33%) |
4 (4%) |
0 (0%) |
| Worst overall | 5 (5%) |
33 (35%) |
39 (41%) |
14 (15%) |
0 (0%) |